Scholarlink

Background <p>Parkinson’s disease (PD) is a progressive neurodegenerative disorder characterized by dopaminergic neuronal loss and chronic neuroinflammation for which effective disease-modifying treatments remain limited. Increasing evidence suggests that herbal extracts can modulate multiple pathological pathways involved in PD. In this study, we developed a novel herbal formulation, ZPT01, and investigated its therapeutic potential using an integrated approach combining in vivo, in vitro, and in silico analyses.</p> Methods and results <p>In 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced mouse models, ZPT01 administration improved motor symptoms, protected dopaminergic neurons, and alleviated neuroinflammatory responses. Network pharmacology analysis identified AKT serine/threonine kinase 1 (AKT1) and prostaglandin-endoperoxide synthase 2 (PTGS2) as key molecular targets, and subsequent molecular docking demonstrated a strong binding affinity between the active compounds and these targets. In vitro experiments further validated these findings, showing that ZPT01 restored the phosphorylation of AKT, a protein product of the <i>AKT1</i> gene, in 1-methyl-4-phenylpyridinium-exposed PC12 cells and suppressed cyclooxygenase-2 (the protein encoded by <i>PTGS2</i>) expression in lipopolysaccharide-stimulated BV2 microglia.</p> Conclusions <p>Our study highlights the neuroprotective and anti-inflammatory properties of ZPT01 and provides promising evidence for its potential as a therapeutic candidate for PD.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

ZPT01, a herbal formula of Zingiberis Rhizoma, Paeoniae Radix and Tribuli Fructus, protects dopaminergic neurons and suppresses neuroinflammation in a Parkinson’s disease model

  • 期刊论文

  • 发表日期：

    2026年4月7日

查看全文
  • Jin Hee Kim,
  • Minji Lee,
  • Myung Sook Oh

摘要

Background

Parkinson’s disease (PD) is a progressive neurodegenerative disorder characterized by dopaminergic neuronal loss and chronic neuroinflammation for which effective disease-modifying treatments remain limited. Increasing evidence suggests that herbal extracts can modulate multiple pathological pathways involved in PD. In this study, we developed a novel herbal formulation, ZPT01, and investigated its therapeutic potential using an integrated approach combining in vivo, in vitro, and in silico analyses.

Methods and results

In 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced mouse models, ZPT01 administration improved motor symptoms, protected dopaminergic neurons, and alleviated neuroinflammatory responses. Network pharmacology analysis identified AKT serine/threonine kinase 1 (AKT1) and prostaglandin-endoperoxide synthase 2 (PTGS2) as key molecular targets, and subsequent molecular docking demonstrated a strong binding affinity between the active compounds and these targets. In vitro experiments further validated these findings, showing that ZPT01 restored the phosphorylation of AKT, a protein product of the AKT1 gene, in 1-methyl-4-phenylpyridinium-exposed PC12 cells and suppressed cyclooxygenase-2 (the protein encoded by PTGS2) expression in lipopolysaccharide-stimulated BV2 microglia.

Conclusions

Our study highlights the neuroprotective and anti-inflammatory properties of ZPT01 and provides promising evidence for its potential as a therapeutic candidate for PD.